Drug Trial Radar · NCT05147675
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for OA
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Dec 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.
Conditions
- Osteoarthritis
- Spinal Arthritis
Interventions
AlloRxBiological
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (adverse events)Time frame: Four year follow-up
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Prodromos Stem Cell Institute
Naples, Florida · Recruiting
Prodromos Stem Cell Institute
Athens, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.